Eli Lilly’s weight-loss pill just passed the test it needed for a second, bigger market.

In the Phase 3 ACHIEVE-4 trial, Foundayo (orforglipron) showed no increase in the risk of major heart events compared with insulin glargine in adults with type 2 diabetes and obesity or overweight at elevated cardiovascular risk. Eli Lilly and Company (NYSE: LLY) released the detailed results in a September 30, 2026 press release. They were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan and published the same day in The Lancet.

The timing matters. Foundayo is approved in the U.S. only for chronic weight management. Lilly has already filed for type 2 diabetes, a market where heart-safety data is effectively a requirement. The release doesn’t mention that filing.

What “Non-Inferior” Means Here

ACHIEVE-4 was built as a safety trial. Under FDA guidance dating to 2008, a new diabetes drug must rule out an unacceptable rise in cardiovascular risk before approval. The bar: the upper end of the 95% confidence interval for the hazard ratio has to stay below 1.8.

Foundayo cleared it. The risk of MACE-4, a composite of cardiovascular death, heart attack, stroke, or hospitalization for unstable angina (sudden, unpredictable chest pain), was 16% lower than with insulin glargine (hazard ratio 0.84; 95% CI, 0.59 to 1.20). That 1.20 upper bound also sits under 1.3, the tighter margin the same guidance set for post-approval studies.

Now the caveat. The 16% gap was not statistically significant (p=0.336). Neither was the 23% lower risk on MACE-3, which drops the angina component (HR 0.77; 95% CI, 0.52 to 1.13; p=0.181). Both intervals cross 1.0. The trial shows Foundayo was not worse than insulin on heart risk. It does not show it was better.

Read the Death Figures Carefully

Lilly’s release leads with mortality. In pre-planned analyses, cardiovascular death was 53% lower with Foundayo (HR 0.47; 95% CI, 0.25 to 0.90) and death from any cause was 57% lower (HR 0.43; 95% CI, 0.25 to 0.75).

Striking numbers. They also carry a footnote: Lilly states these endpoints were not controlled for family-wise type 1 error. Put simply, when a trial checks many outcomes without adjusting for that, some will look strong by chance. Lilly itself says the data suggest potential for broader benefit. Treat it as a signal, not a finding.

The release also leaves out raw event counts, deaths per arm, and median follow-up. Without them, it’s hard to judge how much weight the hazard ratios can bear.

Blood Sugar and Weight

The open-label trial (patients and doctors knew who got which drug) randomized 2,749 adults. Foundayo started at 0.8 mg daily and stepped up every four weeks to a maximum tolerated dose of up to 17.2 mg.

From an average starting A1C of 8.22% (A1C reflects average blood sugar over roughly three months), Foundayo lowered A1C by 1.6 points at 52 weeks, versus 1.0 for insulin glargine. Body weight fell 8.8% on Foundayo. The insulin group gained 1.7%.

At two years, 54.6% of Foundayo patients reached an A1C of 6.5% or lower, against 23.8% on insulin. And 35.9% lost at least 10% of their body weight, versus 3.4%.

Two qualifiers. These figures use the “efficacy estimand,” which models results as if every patient had stayed on treatment. And the two-year numbers, like the death data, weren’t controlled for type 1 error.

Side Effects and Dropouts

Nausea, vomiting, diarrhea, decreased appetite and constipation were the most common side effects, consistent with the drug class. During the 52-week minimum treatment period, 10.6% of Foundayo patients quit because of adverse events.

The release gives no matching dropout rate for the insulin arm. It also omits hypoglycemia (low blood sugar) rates, a key comparison against insulin.

Where the Diabetes Filing Stands

The FDA approved Foundayo for weight management on April 1, 2026, about 50 days after filing, under its Commissioner’s National Priority Voucher pilot program. In June, Lilly said it planned to file for type 2 diabetes under that same program. Its August 5 second-quarter earnings release confirmed the U.S. submission.

No decision date has been disclosed. Approval isn’t guaranteed, and the obesity review’s speed may not repeat.

A Rival Pill Already Has the Heart Label

Novo Nordisk (NYSE: NVO) got there first. In October 2025, the FDA cleared its oral semaglutide, Rybelsus, to reduce major cardiovascular events in high-risk adults with type 2 diabetes. That label rests on SOUL, a double-blind trial of 9,650 patients in which Rybelsus 14 mg cut MACE risk by a statistically significant 14% versus placebo.

The trials aren’t directly comparable. SOUL tested superiority against placebo. ACHIEVE-4 tested non-inferiority against an active drug in an open-label design. No head-to-head heart-outcomes study exists.

Commercially, Foundayo is chasing. It booked $98 million in second-quarter sales, its first quarter on the market. Novo’s Wegovy pill, launched January 5, posted about $354 million in its first quarter.

Who Else Has a Stake

Lilly didn’t discover the molecule. Chugai Pharmaceutical (Tokyo Stock Exchange: 4519) did, and licensed it to Lilly in 2018. Per Lilly’s 2023 annual report, as disclosed by Chugai, Chugai is eligible for tiered royalties from mid-single digits to low teens on worldwide net sales. The ACHIEVE-4 release names Chugai but not its listing or economics.

A separate Phase 3 heart-outcomes study, ATTAIN-OUTCOMES, is ongoing in adults with obesity or overweight and established cardiovascular or kidney disease. Lilly gave no readout timeline.

Sources

• Eli Lilly and Company: Lilly’s oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study, PRNewswire, September 30, 2026. Primary source release.
• Eli Lilly and Company: Lilly reports second-quarter 2026 financial results (Form 8-K exhibit, SEC EDGAR), cited for the U.S. type 2 diabetes submission and Foundayo’s $98 million Q2 2026 sales, neither of which appeared in the ACHIEVE-4 release.
• Eli Lilly and Company: Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials, PRNewswire, June 8, 2026, cited for Lilly’s plan to file under the Commissioner’s National Priority Voucher program.
• Healio: FDA approves Foundayo, an oral GLP-1, for adults with obesity, cited for the April 1, 2026 obesity approval and the 50-day review under the voucher program.
• Circulation: Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs? Ten Years of FDA Guidance Requirements, cited for the FDA’s 2008 cardiovascular-safety thresholds (1.8 pre-approval, 1.3 post-approval).
• Novo Nordisk: FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction in adults with type 2 diabetes, PRNewswire, October 17, 2025, cited for competitive context on Rybelsus and the SOUL trial.
• TCTMD: Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients, cited for SOUL’s 9,650-patient, placebo-controlled design.
• Fierce Pharma: Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom, cited for Wegovy pill launch timing and first-quarter sales.
• Chugai Pharmaceutical: Eli Lilly and Company Discloses Form 10-K Including Orforglipron Related Information, cited for Chugai’s Tokyo listing and tiered royalty terms on orforglipron.

Editorial Disclosure

This article reports on clinical trial data from the Phase 3 ACHIEVE-4 trial of Foundayo (orforglipron), based on a press release issued by Eli Lilly and Company on September 30, 2026, and on results presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). Securities discussed: Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), and Chugai Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4519). Foundayo’s regulatory history and pending type 2 diabetes submission, the FDA’s cardiovascular-safety thresholds, competitive data on Rybelsus and the SOUL trial, product sales figures, and Chugai’s royalty terms were drawn from independent sources cited above, since the original release did not address them. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Eli Lilly and Company, Novo Nordisk, Chugai Pharmaceutical, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. Statements regarding the timing and outcome of the FDA’s review of Foundayo for type 2 diabetes, potential cardiovascular or mortality benefits, future results from ATTAIN-OUTCOMES, commercial performance, and royalty payments are forward-looking statements. They involve substantial risks, regulatory uncertainties, and scientific variables; actual clinical outcomes, development timelines, regulatory decisions, and commercial results may differ materially. Pharmaceutical investments carry significant financial risk. Drug development and commercialization are subject to clinical failure, regulatory rejection, safety findings, pricing pressure, and market competition, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, see our full DISCLAIMER.